Chapter from the book *Brain Injury - Pathogenesis, Monitoring, Recovery and Management*

Downloaded from: http://www.intechopen.com/books/brain-injury-pathogenesis-monitoring-recovery-and-management

Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
1. Introduction

Traumatic brain injury (TBI) is a spectrum of pathological changes in the brain that result from application of external mechanical force(s) leading to temporary or permanent impairment of neurological function. TBI is a global health problem. In 1990, 9.5 million individuals worldwide sustained a TBI severe enough to warrant medical attention or result in death (Corrigan, Selassie, & Orman 2010). In the United States, the annual incidence of TBI is 506.4 per 100,000 population (Langlois JA 2006), in Europe it is 235 per 100,000 population (Tagliaferri et al. 2006), and in Asia it is reported to range from 160 (Gururaj G 2004) to 344 (Chiu et al. 1997) per 100,000 population (incidence rate from United States is inclusive of emergency department visits, hospital discharges and deaths, incidence rates from Europe and Asia are inclusive of hospital discharges and deaths only). Severe TBI has long term consequences for the individual and the society. In the United States, it is estimated that annually 43.1% (124,000) of the individuals discharged after acute hospitalization for TBI (Selassie et al. 2008) develop long term disability. The prevalence of individuals in the United States with disability secondary to TBI is estimated to be 3.2 million (Zaloshnja et al. 2008). The total life time cost of treating TBI cases in the United States, including loss of productivity, is estimated to be $60.4 billion for the year 2000 (Corrigan, Selassie, & Orman 2010). The enormous economic and social burden imposed by TBI demands aggressive measures to prevent and treat TBI.

Technological developments and better understanding of brain physiology have resulted in a dramatic improvement in mortality related to TBI. Mortality rates declined precipitously between 1970 and 1990, likely related to the routine use of computed tomography (CT) scans and intracranial pressure (ICP) monitoring, as well as improvement in trauma resuscitation generally. However, despite more recent advances in neuromonitoring and neuroimaging, mortality has remained steady at approximately 35% since the 1990s (Stein et al. 2010). The reasons for this lack of progress are multifactorial; no doubt the increase in severe TBI among the elderly is a contributing factor (Colantonio et al. 2008). Nevertheless, the field of neurotrauma has suffered from the lack of well organized multicenter, randomized clinical trials designed to assess the efficacy of the newer techniques and interventions for the management of TBI. Efforts to design and conduct clinical trials in TBI have been challenging for many reasons including the heterogeneity of the disease, barriers to recruitment, and lack of standardized management protocols across centers (Narayan et al. 2002). This chapter presents an overview of the pathophysiology and basic principals of management of TBI, and the challenges facing the scientific community in dealing with this debilitating disorder.
2. Mechanism

TBI results from the application of external force to cranium and its contents. The severity of injury is determined by the nature, magnitude and duration of load applied to cranium and the force vector (rotational, translational or angular) (Gennarelli 1993). Force applied to cranium can be static (delivered over more than 200 milliseconds) or dynamic (delivered over less than 200 milliseconds). Static loading is a less common cause of TBI in clinical situations, and usually leads to focal brain damage. Dynamic loading is a more common cause of TBI, and produces more complex and widespread brain damage. Dynamic loading itself results from direct blow to the cranium (contact load), or rapid acceleration or deceleration of the cranium (inertial load) that causes differential motion of the brain relative to the skull. Inertial loading can cause translational movement (linear motion of brain in the skull), rotational movement (shearing motion of different layers of brain in relation to one another), and angular movement (a combination of translational and rotational movements). In most clinical situations, severe TBI is initiated by impact to the head of a solid object at a high velocity, leading to brain damage by a combination of contact and inertial loading (Graham, Adams, & Gennarelli 1988).

Traumatic brain injury can be focal or diffuse. Focal injury manifests as fractures, contusion or hematoma with mass effect. Contact loading, wherein a significant force is applied to cranium, can cause fracture at the site of impact with underlying contusion or epidural/subdural hematoma. If contact loading also produces translational acceleration or deceleration of the brain within the cranium, it can also cause focal damage by compression of brain under the site of impact (coup contusion) or remote from it (counter coup contusion). Diffuse brain injury results from rotational or angular acceleration or deceleration of the brain; the presentation can vary from transient loss of consciousness (concussion) to diffuse axonal injury (DAI) with prolonged coma. With increasing magnitude of inertial force progressively deeper structures in the brain suffer DAI (Adams et al. 1989). In clinical situations focal lesions and DAI frequently coexist (Skandsen et al. 2010).

3. Pathophysiology

TBI is not a static event, but a constantly evolving dynamic process. The initial insult leads to instant brain damage known as primary brain injury. Primary brain injury triggers a cascade of events that cause brain edema, intracranial hypertension, and consequent ischemia, categorized as secondary brain damage (Enriquez & Bullock 2004). In diffuse injury the primary insult is at the cellular level and initiates events that lead to release of excitatory neurotransmitters, loss of ionic homeostasis, disruption of ATP production, toxicity from free radical production, loss of auto regulation and breakdown of blood brain barrier (BBB). These pathological changes lead to secondary injury. Similar secondary changes also occur in the region surrounding an area of contusion or traumatic hematoma, with a zone of ischemia and swelling developing around the focal injury. Tissue in this “ischemic penumbra” is at risk of dying but also salvageable (Schroder et al. 1995; Leker & Shohami 2002). Treatment of acute TBI is directed at minimizing secondary brain damage that follows focal as well as diffuse TBI.

A good understanding of cellular and biochemical changes that follow brain trauma is required for the optimal management of brain injury, and for directing future research aimed at design of new therapies and protocols. A detailed discussion of these changes is
beyond the scope of this chapter; however, a brief summary is presented. Following trauma, the excitatory amino acid glutamate is released from the presynaptic neurons and activates both post synaptic neurons and glial cells. Under physiological conditions both glial cells and postsynaptic neurons actively remove glutamate from the synaptic space. Following trauma the high levels of glutamate activate receptors in the cell membranes of postsynaptic neurons and glial cells, resulting in \( \text{Ca}^{2+} \) influx into the cell with consequent free radical formation and increased oxidative stress. Calcium ions also accumulate in the mitochondria leading to mitochondrial membrane damage and disruption of energy cycle. These events eventually trigger necrosis and apoptosis in the cells (Enriquez & Bullock 2004; Shohami et al. 1997).

TBI disrupts the BBB that allows fluid to move from intravascular compartment to extravascular compartment in the brain with resultant brain swelling and intracranial hypertension, which in turn leads to fall in cerebral perfusion thus further exacerbating brain ischemia. Aquaporins, matrix metalloproteinases and vasoactive inflammatory agents are potential mediators of BBB breakdown following trauma (Donkin & Vink 2010). A porous BBB allows infiltration of inflammatory cells into damaged brain. These cells (neutrophils and macrophages) release free radicals and cytokines into the brain tissue accentuating the damage (Soares et al. 1995).

4. Initial management at the scene of injury

Pre-hospital management is a critical step in the overall care of acute brain injury. Early institution of optimal care will minimize secondary injury while the patient is transported to a tertiary care facility. About half the deaths following TBI occur within first 2 hours of the injury (Badjetia, Carney et al. 2008) thereby signifying the importance of optimal pre-hospital care.

Pillars of pre-hospital care are restoring and maintaining airway, breathing and circulation (ABC) (Dewall 2010). The cervical spine must be immobilized as the patient is resuscitated, and spine precautions should be maintained till the patient is transferred to a trauma center. Intubation is indicated to secure the airway if the Glasgow Coma Scale (GCS) is less than 9, if the patient is hypoxic (\( \text{SpO}_2 < 90\% \)) despite supplemental oxygen, or if the patient is unable to maintain a patent airway (Gabriel et al. 2002). The \( \text{SpO}_2 \) should be kept above 95%, while maintaining eucapnea with an end tidal carbon dioxide (Et\( \text{CO}_2 \)) of 35 to 40 mm Hg (Badjatia, Carney et al. 2008). Hypotension accelerates secondary injury, and must be promptly recognized and treated. Systolic blood pressure below 90 mm Hg has been shown to increase mortality by two fold in TBI (Chesnut et al. 1993). Intravenous access should be promptly established, and normal saline is a reasonable choice for pre hospital fluid resuscitation (Dewall 2010). Intravenous dextrose should be administered only if blood glucose is less than 70 mg/dl (Badjatia, Carney et al. 2008). Persistent hypotension should prompt search for extracranial injury or spinal cord injury. Neurogenic hypotension presents with bradycardia and hypotension as opposed to hypovolemic shock that is characterized by tachycardia and hypotension.

Glasgow coma scale (GCS) and pupillary response should be documented after the ABCs of resuscitation are complete, and if more than one provider is available, this can be done while the ABCs are being secured. Assessment of the GCS and pupillary response in pre-hospital setting allows the emergency medical personnel to communicate to the receiving hospital the neurological status of the patient, screen for cerebral herniation and trend the
neurological status (Badjatia, Carney et al. 2008). A quick secondary survey for extracranial injuries should be performed prior to transport (Dewall 2010). Timely transport of these patients to tertiary care center is critical to a favorable outcome. Patients with severe TBI (GCS < 9) should be transported directly to a facility equipped with an immediately available CT scanner, prompt neurosurgical care and the ability to monitor intracranial pressure and treat intracranial hypertension (Badjatia, Carney et al. 2008), even if it is not the closest hospital (Hartl et al. 2006). Mortality can increase by 50%, if a severe TBI patient is not directly transported to such a facility (Hartl et al. 2006). Mode of transport (by road or air) should be chosen to minimize the transit time (Dewall 2010), as mortality following acute subdural hematoma has been shown to be directly linked to time to surgical intervention (Seelig et al. 1981).

5. Medical management

5.1 Principles of intensive care
Management of the patient with traumatic brain injury is directed predominantly at minimizing and preventing secondary brain injury, which can result from intracranial or systemic causes. Although the mechanisms of secondary brain injury are incompletely understood, inadequate cerebral perfusion and oxygenation are integral factors. Systemic hypoxia and hypotension are significantly associated with increased morbidity and mortality. This effect was demonstrated in a data set from the Traumatic Coma Data Bank, in which a single episode of systemic hypotension was associated with double the risk of death (Chesnut et al. 1993; Bratton et al. 2007). This observation serves to demonstrate that good basic critical care is paramount. Current guidelines recommend a systolic blood pressure greater than 90 mmHg as a resuscitation end-point (Bratton et al. 2007). Adequate fluid resuscitation is important, but vasopressors should be used if fluids are insufficient to maintain adequate systemic blood pressures. Intubation and mechanical ventilation are necessary for patients presenting with severe brain injuries in order to ensure adequate oxygenation and ventilation, and to minimize the risk of aspiration (Valadka & Robertson 2007). Admission to a dedicated neuroscience critical care unit, when available, may also result in improved outcomes (Patel et al. 2005).

Ventilator management in patients with severe TBI presents some unique challenges because of the effect of PaCO$_2$ on cerebrovascular autoregulation. Hyperventilation has long been recognized as an effective means for treating acutely elevated intracranial pressure. Hyperventilation results in a systemic respiratory alkalosis, which in turn lowers the pH of the cerebrospinal fluid. In patients with intact cerebral autoregulation, this change in pH results in constriction of cerebral arterioles, thereby decreasing the cerebral blood volume and lowering the intracranial pressure. As a result of this phenomenon, routine hyperventilation of TBI patients has been advocated in the past. However, experimental evidence has demonstrated that the vasoconstrictive effect is relatively short-lived, (Muizelaar et al. 1988) and there is concern that continued hyperventilation could potentiate cerebral ischemia (Bratton et al. 2007). Furthermore, subsequent efforts to correct an iatrogenic respiratory alkalosis sometimes precipitate rebound increases in intracranial pressure (Valadka & Robertson 2007). For these reasons, hyperventilation is usually employed only as a temporizing measure in patients suffering an acute neurological decline. The relationship between PaCO$_2$ and cerebral blood flow becomes particularly problematic in TBI patients with co-morbid lung injury. Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are not uncommon in the neurological critical care unit. Since the
publication of the ARDSnet trial in 2000, the mainstay of therapy for patients with ALI and ARDS has been lung-protective ventilation, which minimizes barotrauma to the lungs by employing lower tidal volumes (The Acute Respiratory Distress Syndrome Network 2000). This strategy results in a moderate degree of hypercapnea and hypoxemia. While lung-protective ventilation significantly improved mortality in the study population, the relative hypercarbia and hypoxemia may have deleterious effects in a patient who is at risk for cerebral edema, ischemia, or vasospasm. Randomized trials in TBI patients with ARDS are lacking. Monitoring of cerebral perfusion and oxygenation, which is discussed in subsequent sections, is particularly crucial in this scenario (Young et al. 2010).

Because of the brain’s role in regulating metabolism, patients with severe traumatic brain injury demonstrate a number of metabolic derangements which ultimately result in systemic catabolism (Cook, Peppard, & Magnuson 2008). Adequate nutritional support is essential to forestall adverse consequences, including protein loss and immunocompromise (Sacks et al. 1995). Early institution of nutritional support has a significant impact on mortality and decreases the rate of hospital-acquired infections (Hartl et al. 2008; Taylor et al. 1999). Patients with severe TBI will require replacement of approximately 140% of their resting energy expenditure, though this requirement will be decreased somewhat in the setting of pharmacological paralysis or deep sedation. Protein requirements are estimated at about 1.5-2 grams/kg of protein (Cook, Peppard, & Magnuson 2008). Close monitoring is essential to ensure adequate supplementation and avoid complications such as hyperglycemia. Early hyperglycemia has been associated with poor outcome in TBI patients (Liu-DeRyke et al. 2009), but intensive glycemic control may exacerbate metabolic stress in some patients (Vespa et al. 2006). Although the optimal glucose range for TBI patients has yet to be determined, our institution has chosen 140-180 mg/dL as a reasonable target range.

Because of their increased sympathetic tone, severity of illness, and degree of immobility, TBI patients are at high risk of complications of critical illness including infection and thromboembolism. Long-term use of prophylactic antibiotics is discouraged, though there is some evidence that brief treatment at the time of endotracheal intubation reduces the incidence of ventilator-associated pneumonia (Sirvent et al. 1997). Fevers are common in patients with traumatic brain injury, and may represent an underlying infection, hypothalamic dysfunction, or other non-infectious cause. Hyperpyrexia must be investigated exhaustively in order to rule out the possibility of an infectious etiology; however, any fever in a patient with neurological injury must be treated aggressively. Increased temperature results in increased cerebral blood flow, which can exacerbate intracranial hypertension and reduce intracranial compliance (Segatore 1992). Furthermore, animal studies have indicated that hyperthermia can increase infarct size and potentiate cellular damage (Dietrich et al. 1996; Dietrich & Bramlett 2007). For these reasons, aggressive treatment of fever in brain-injured patients is warranted. First-line treatments generally include antipyretics such as acetaminophen; cooling blankets, fans, and chilled fluids have also been employed (Johnston et al. 2006). Control of shivering is also important, as shivering can increase metabolic demand and impede efforts to maintain normothermia (Badjatia, Strongilis et al. 2008).

Prevention of thromboembolic events is a major consideration in patients with severe TBI, especially in poly-trauma patients. Mechanical prophylaxis with graduated compression stockings and/or pneumatic compression devices is recommended, though these interventions may be contraindicated in the presence of significant injury to the lower extremities (Bratton et al. 2007). Pharmacological prophylaxis with unfractionated (UH) or
low-molecular weight heparin (LMWH) has been the subject of some debate. There is concern that use of pharmacological interventions could result in exacerbation of cerebral contusions, intracranial hemorrhage, and systemic bleeding. Evidence in a neurosurgical population indicates that pharmacological prophylaxis used in conjunction with mechanical devices is more effective than mechanical measures alone (Nurmohamed et al. 1996; Agnelli et al. 1998). Recent observational evidence suggests that initiation of prophylactic treatment with LMWH within 48 hours of injury or neurosurgical intervention is effective and associated with an acceptably low risk of complications (Norwood et al. 2008; Dudley et al. 2010). Unfortunately, the most effective agent and dosing strategy is yet to be determined.

5.2 Cerebral edema, intracranial hypertension and cerebral perfusion pressure

The components of the intracranial compartment under normal circumstances consist of brain tissue, cerebrospinal fluid, and blood. Because the intracranial contents are contained within the rigid confines of the skull, any increase in volume—in the form of cerebral edema or a pathological mass lesion—must be met with a compensatory decrease in one of the other components, or the ICP will rise. Elevated ICP can result in cerebral ischemia, an important cause of secondary brain injury, by reducing cerebral perfusion pressure (CPP):

\[
\text{CPP} = \text{MAP} - \text{ICP}
\]

Where MAP is the mean arterial pressure.

There is a considerable amount of debate regarding the relative importance of CPP and ICP thresholds. On one hand, observational data indicates that ICP > 20 mmHg is an independent predictor of morbidity and mortality (Helmy, Vizcaychipi, & Gupta 2007; Valadka & Robertson 2007; Robertson et al. 1999; Hiler et al. 2006; Czosnyka et al. 2005); however, good outcomes are possible even in the setting of exceptionally high ICPs, provided that cerebral perfusion is maintained. As a consequence, some centers advocate a CPP guided strategy, whereas other clinical protocols focus predominantly on ICP and minimization of cerebral edema (Eker et al. 1998). Guidelines recommend ICP monitoring in patients with a Glasgow Coma Score (GCS) ≤ 8 who have abnormalities visible on computed tomography (CT). In the absence of CT abnormalities, ICP monitoring is indicated in comatose patients meeting 2 of the following criteria: age > 40 years, presence of motor posturing on exam, and/or SBP < 90 mmHg(Bratton et al. 2007). ICP values in excess of 20 mmHg are considered pathological, though it is important to note that herniation can occur at lower ICPs, especially in the presence of intracranial mass lesions (Bratton et al. 2007).

The situation is complicated by the fact that the relationship between ICP and CPP is affected by the integrity of cerebrovascular autoregulatory mechanisms. When cerebral autoregulation is intact, a fall in CPP is met with reflex cerebral vasodilation. This can precipitate an increase in ICP, thereby further diminishing cerebral perfusion (Robertson 2001). In this setting, efforts to augment CPP artificially may abort a destructive cycle and arrest ongoing secondary brain injury. However, if CPP falls outside of the range of normal autoregulation, or if cerebral autoregulation is impaired, this relationship is reversed: ICP will rise in a linear fashion with increasing CPP, and artificial augmentation of cerebral blood flow may result in worsening cerebral edema and hyperemia. Initially, observational data using historical controls lead to the conclusion that CPP should be maintained at > 70 mmHg. However, in a retrospective analysis of the Selfotel trial, Juul et al. found that there was no outcome benefit obtained by maintaining CPP > 60; interestingly, ICP ≥ 20 was the
most powerful predictor of outcome (Juul et al. 2000). The only randomized trial to date addressing the question of CPP vs. ICP was published by Robertson, et al. in 1999. In this trial, the CPP in one group was maintained at > 70 mmHg; in the other group, the ICP was maintained at ≤ 20 mmHg and CPPs as low as 50 mmHg were permitted. The investigators found no significant difference in outcome, but the CPP-targeted strategy carried five times the risk of ARDS (Robertson et al. 1999). An increasing appreciation of the role of cerebrovascular autoregulation in secondary brain injury has led some investigators to incorporate assessment of autoregulatory function into clinical protocols. The most readily available measure is the pressure reactivity index (PRx), which is a moving correlation coefficient calculated from measurements of ICP and MAP (Czosnyka et al. 1998). Centers that employ this measurement have reported that patients with intact autoregulation (PRx is low) have improved outcomes when managed according to a CPP guided paradigm, whereas those with impaired autoregulation (PRx is elevated) benefit from an ICP targeted strategy (Howells et al. 2005). Clearly, this observation warrants additional study.

Interventions to control intracranial hypertension generally act to decrease the volume of one component of the intracranial compartment: blood, brain, or CSF. First line interventions include patient positioning, adequate sedation and analgesia, and maintenance of normothermia. The head of the bed should be elevated and any obstructions to jugular venous outflow, such as cervical collars, should be minimized. Adequate sedation and analgesia serve to minimize ventilator dyssynchrony, lower intrathoracic and intraabdominal pressure, and decrease agitation (Helmy, Vizcaychipi, & Gupta 2007). Treating systemic fever can mitigate the associated CNS hyperemia prevent shivering and rigors, which often result in increased ICP. If an external ventricular drain is present, diversion of cerebrospinal fluid can be helpful as well.

Use of hyperosmolar substances is the mainstay of therapy for cerebral edema, with or without associated intracranial hypertension (Bhardwaj 2007). Infusion of a hyperosmolar substance serves to generate an osmotic gradient across the blood-brain-barrier, which reduces cerebral edema by drawing water out of the brain tissue. Mannitol and hypertonic saline (HTS) are the most commonly used agents in clinical practice. Mannitol is generally given as a bolus in doses ranging from 0.25-1.5 grams/kg. Hypertonic saline can be administered as a bolus or as a continuous infusion. For continuous use, concentrations ranging from 2% to 7.5% have been reported; boluses of 23.4% NaCl can be used in the setting of acute neurological decline. Use of either agent can result in rapid improvement in ICP; therefore, selection of the appropriate treatment will depend upon the clinical scenario. Mannitol can easily be infused through a peripheral intravenous line, whereas concentrations of HTS > 2% require central access. Mannitol acts as an osmotic diuretic, and can result in intravascular volume depletion, hypokalemia, and hypotension. There is concern that repeated dosing can result in renal impairment, especially if the drug is not adequately cleared by the kidneys; this can be monitored by calculating the osmolal gap. Hypertonic saline, on the other hand, acts as a volume expander and has been shown to be an effective means of reducing ICP even in patients who did not respond to mannitol (Ogden, Mayer, & E. Sander Connolly 2005; Vialet et al. 2003; Schwarz et al. 2002). Potential adverse events include congestive heart failure and hyperoncotic hemolysis; rapid administration of concentrated solutions may also result in transient hypotension. Either agent has the potential to accumulate in brain tissue in the presence of disruption of the blood-brain-barrier. Also, continued exposure to a hypertonic environment induces the generation of idiogenic osmoles within brain tissue, possibly setting the stage for rebound.
intracranial hypertension when the serum osmolarity begins to fall (Diringer & Zazulia 2004). Consequently, close monitoring of the patients’ ICP, CPP, serum sodium, and serum osmolarity is required. Despite the lack of convincing evidence, general consensus is that driving the serum sodium above 160 mEq/L is rarely beneficial, and most clinicians try to maintain the serum osmolarity below 320 mOsm/L (Hays et al. 2011).

When intracranial hypertension persists despite maximal osmotherapy, ICP may be controlled by interventions designed to decrease the cerebral blood volume. This can be accomplished by suppressing brain metabolism, either by inducing a pharmacological coma or with therapeutic hypothermia. Induction of a pharmacological coma is usually accomplished using barbiturates, such as pentobarbital. Barbiturates have been shown experimentally to mitigate the development of brain edema (Mishina & Yabuki 1994), decrease cerebral metabolism, and lower cerebral blood flow (Kassell, Hitchon et al. 1980). Early experimental data suggested a neuroprotective effect in models of focal cerebral ischemia (Smith et al. 1974); however, subsequent small-scale clinical trials were disappointing (Ward et al. 1985; Kassell, Peerless et al. 1980). Studies in brain injured patients indicate that barbiturates may be less effective than mannitol as an initial intervention, but nevertheless are useful in patients who have failed maximal osmotherapy (Eisenberg et al. 1988; Schwartz et al. 1984; Marshall et al. 2010). Pentobarbital has a number of undesirable side-effects including systemic hypotension, decreased gastric motility, and bone marrow suppression (Meyer et al. 2010). In addition, continuous infusion of pentobarbital results in delayed drug clearance, which can delay detection of neurological improvement or decline. Continuous electroencephalography allows the clinician to titrate to burst-suppression, thereby ensuring that the minimum effective dose is employed. Several other agents, including propofol and midazolam, can be used to suppress CNS metabolism and induce burst-suppression, though they do not appear to be as effective as barbiturates in the treatment of intracranial hypertension (Meyer et al. 2010; Stewart et al. 1994). Unfortunately, no comparative trials are available.

Induced hypothermia has been investigated as a neuroprotective strategy in many disease states, and is currently the standard of care for comatose patients following cardiac arrest (Bernard & Buist 2003; Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest 2002; Bernard et al. 2002). Moderate hypothermia has been shown to decrease the cerebral metabolic rate considerably (Rosomoff & Holaday 1954). In models of ischemia, it serves to decrease the concentrations of lactate and excitotoxic neurotransmitters (Illievich et al. 1994). Although clinical trials have failed to demonstrate an outcome benefit for early hypothermia in traumatic brain injury (Clifton et al. 2001), there is ample evidence that moderate hypothermia is an effective intervention for intracranial hypertension (Meyer et al. 2010). Most investigators used a target temperature between 33-35°C, which can be achieved using a variety of cooling methods (Marion et al. 1993; Marion et al. 1997; Liu et al. 2006; Qiu et al. 2007; Jiang, Yu, & Zhu 2000; Shiozaki et al. 1993). Complications of moderate hypothermia include an increased susceptibility to infection, cardiac arrhythmias, coagulopathy, and electrolyte disturbances. Iatrogenic hypothermia can also mask a fever, and potentially delay the diagnosis of an underlying infection; for that reason, the authors advocate following the white blood cell count and obtaining periodic cultures in all hypothermic patients. Shivering is often encountered during the induction and rewarming phases, and this can counteract the beneficial effects of hypothermia on ICP and cerebral metabolic rate. Pharmacological paralysis is often used to prevent shivering, but other interventions including magnesium, dexmedetomidine, and meperidine have also been
used successfully (Weant et al. 2010). Many of these complications of systemic hypothermia may be mitigated by the use of selective brain cooling devices, which are employed at some institutions (Qiu et al. 2006; Liu et al. 2006).

The duration of hypothermia therapy can vary widely depending upon the clinical needs of the individual patient; reports in the literature range from 24 hours to 14 days (McIntyre et al. 2003). The rewarming phase of therapy is critical due to the risk of mitochondrial injury, vascular dysregulation, and rebound increases in ICP (Jiang, Yu, & Zhu 2000; Jiang & Yang 2007; Povlishock & Wei 2009). Although the optimum rewarming rate has yet to be determined, most authors advocate rates of approximately 0.5-1°C/hour (Bernard & Buist 2003; Bernard et al. 2002; Alzaga, Cerdan, & Varon 2006). At our institution, cooling is generally performed for a minimum of 48 hours. If the patient’s ICP remains well-controlled during that period, rewarming is initiated at a rate of approximately 0.5°C/hr. In the event of recurrent intracranial hypertension, rewarming is halted for an additional 12-24 hours before repeating the attempt.

5.3 Advanced neuromonitoring

In an effort to elucidate the mechanisms of secondary brain injury in severe TBI and improve outcomes from this highly morbid condition, a number of technologies have been developed to provide information regarding brain function, oxygenation, and perfusion. Neurophysiologic techniques such as electroencephalography have been used intermittently in brain injured patients for decades; however, recent evidence suggests that continuous monitoring may provide considerable benefit. Similarly, recent technological advances have enabled the bedside assessment of cerebral perfusion and oxygenation at the bedside. These techniques will be discussed briefly in the following sections.

5.3.1 Continuous electroencephalography

Electroencephalography (EEG) is used for a variety of indications in brain injured patients. Continuous electroencephalography (cEEG) can be employed for the diagnosis and treatment of seizures, in order to titrate barbiturate therapy, as an indicator of cerebral ischemia, and to provide information regarding prognosis. Seizures are a well known complication of TBI, and can contribute to ongoing secondary brain injury (Claassen et al. 2004; Vespa et al. 1999). The incidence of electrographic seizures in severely head injured patients has been reported at 22-33%, with more than half of these events being clinically silent (Vespa et al. 1999; Ronne-Engstrom & Winkler 2006). Moreover, investigators utilizing intracortical electroencephalography report recording several seizures which were occult on simultaneous scalp EEG (Waziri et al. 2009). Seizures are both more likely and more difficult to detect in comatose patients, suggesting that these patients are most likely to benefit from continuous EEG (cEEG) monitoring (Claassen et al. 2004). Early post-traumatic seizures have been associated with adverse physiological events, including elevation of intracranial pressure and an increase in the lactate to pyruvate ratio (Vespa et al. 2007). There is no clear association between isolated post-traumatic seizures and increased mortality; however, case series suggest that post-traumatic status epilepticus carries a high risk of death (Vespa et al. 1999; Bratton et al. 2007). Although most investigators advocate treatment of early post-traumatic seizures as a means for reducing secondary brain injury, it remains to be determined if this intervention improves patient outcome.
5.3.2 Cerebral blood flow and brain tissue oxygenation

The recognition of cerebral ischemia as a major contributing factor to secondary brain injury has generated considerable interest in measurement of cerebral perfusion in head injured patients. A number of imaging techniques, including transcranial Doppler ultrasound, xenon-enhanced CT, CT perfusion imaging, perfusion weighted MRI, and positron emitted tomography are available to evaluate cerebral perfusion. Using these techniques, investigators have demonstrated that cerebral blood flow following head trauma follows three distinct hemodynamic phases: initial hypoperfusion, accompanied by reduced cerebral metabolic rate of oxygen (CMRO$_2$); subsequent hyperemia, without an associated increase in CMRO$_2$, which may be associated with intracranial hypertension; followed by a period in which cerebral blood flow (CBF) may be reduced secondary to vasospasm (Martin et al. 1997). However, the physiological and pathophysiological significance of these phases has been debated, and significant regional variation of cerebral perfusion is present (Wintermark et al. 2004). As discussed previously, cerebral perfusion can be significantly affected by systemic factors that impact the MAP and the CPP; the magnitude of this effect is dependent upon the individual’s autoregulatory status (Czosnyka et al. 1998; Howells et al. 2005). Furthermore, the reports of the incidence and significance of cerebral vasospasm after trauma are variable, and likely are affected by the mechanism of injury (Martin et al. 1997; Zubkov et al. 2000). MR, CT, and PET based imaging techniques provide information regarding cerebral perfusion over large regions of the brain parenchyma, but for the most part the data obtained is useful only for a single time point. Transcranial Doppler can be performed for extended periods of time, but it is limited to the evaluation of the large vessels surrounding the Circle of Willis, and image quality is highly operator-dependent. More recently, parenchymal monitors have been used to provide a continuous measurement of cerebral blood flow in a specific, small region of tissue using thermal diffusion. This device is placed in the perilesional white matter via a burr hole in the skull. Use of CBF monitoring is currently employed in some centers and may provide a method for continuous assessment of cerebrovascular autoregulation in the future (Rosenthal et al. 2011).

In addition to CBF, brain oxygenation is often used as an indicator of cerebral ischemia. For decades, brain oxygenation could be assessed only indirectly, by intermittent sampling of the jugular venous blood. However, in the 1990s, a fiber-optic catheter which permitted continuous assessment of jugular venous oxygen saturation (SjvO$_2$) became available (Ritter et al. 1996). SjvO$_2$ provides a global measure of cerebral oxygenation and can permit early detection of cerebral ischemia. Studies have shown that jugular venous desaturations (< 50%) are correlated with poor outcome, especially if prolonged and/or recurrent (Gopinath et al. 1994). However, cerebral metabolism in TBI demonstrates regional heterogeneity, and a global measure such as SjvO$_2$ may not permit detection of focal regions of ischemia (Valadka et al. 2000). More recently, intraparenchymal monitors have become available for the purpose of monitoring local brain tissue oxygen tension (PbrO$_2$). These monitors are typically inserted in normal-appearing brain tissue adjacent to a focal lesion, or in the right frontal region in the setting of diffuse axonal injury. As with SjvO$_2$ monitoring, episodes of desaturation detected by PbrO$_2$ monitoring have been shown to correlate with increased mortality (Stiefel et al. 2005). The critical value appears to be approximately 15 mmHg, though some clinicians prefer a treatment threshold of 20 mmHg (Bratton et al. 2007). Various investigators have studied the relationships between PbrO$_2$ and more conventional clinical parameters. In particular, positive correlations have been described between PbrO$_2$ and various determinants of oxygen supply to the CNS, including FiO$_2$, PaO$_2$, CPP, and...
hemoglobin concentration (Stiefel et al. 2005). However, studies using PET imaging and monitoring of the arteriovenous oxygen tension difference have provided evidence that barriers to local oxygen diffusion, rather than determinants of oxygen supply, are significant determinants of PbrO₂ (Rosenthal et al. 2008; Bratton et al. 2007).

A drop in cerebral oxygenation (as measured by PbrO₂ or SjvO₂) should prompt an investigation for an underlying cause, such as subclinical seizures; an expanding mass lesion; suboptimal CPP; or systemic derangements such as hypotension or worsening lung function. The two monitoring methods are often complementary. For instance, PbrO₂ is more sensitive to changes in the arterial oxygen content, and would be more likely to signal the expansion of a nearby contusion (Valadka et al. 2000). Cerebral oxygen desaturation can be successfully treated using measures designed to augment oxygen delivery, such as optimizing the CPP, increasing the fraction of inspired oxygen (FiO₂), and transfusion of red blood cells depending upon the patient’s specific clinical characteristics; however, these interventions carry some risk. Normobaric hyperoxia has been shown to improve PbrO₂ as well as some other markers of brain metabolism, but prolonged use exposes the patient to the risk of oxygen toxicity (Tisdall et al. 2008). Similarly, the optimal transfusion threshold for brain injured patients has yet to be determined, and injudicious use of blood products carries the risk of transfusion related lung injury, as well as other potential complications. A recent trial of 70 patients reported that a group of patients with severe TBI who received PbrO₂ guided therapy (goal > 20 mmHg) demonstrated improved mortality and better functional outcomes than those managed using traditional ICP (< 20 mmHg) and CPP goals (> 60 mmHg) (Spiotta et al. 2010). However, this trial relied on historical controls, and the authors did not report on the incidence of ARDS or other medical complications in either cohort. A multicenter randomized controlled trial addressing the use of PbrO₂ monitoring in severe TBI is currently underway.

6. Surgical management

Surgical intervention is indicated in TBI for control of intracranial hypertension or restoring integrity of structures covering the brain as in compound injuries. High ICP, following TBI, can result from a focal intracranial hematoma or diffuse brain swelling. “Moderate” sized contusion hematomas can present the surgeon with a dilemma about whether to operate or observe the patient. Presence of alcohol or drugs on board can further compound the situation. Close clinical observation, ICP monitoring, and a follow-up head CT scan can help to guide the therapy, but ultimately surgeon’s experience and clinical judgment plays a crucial role in decision making.

Evidence based guidelines are available to help with decision-making (Bullock et al. 2006, 2006; Bullock et al. 2006, 2006, 2006). Any mass lesion with progressive neurological decline referable to the lesion should be operated upon. A supratentorial lesion with a midline shift of 5 mm or more and effacement of the basal cisterns, and a posterior fossa lesion with compression or distortion of fourth ventricle or effacement of basal cisterns or obstructive hydrocephalus in patients with GCS of 8 or less should be evacuated. Epidural hematomas (EDH) larger than 30 cm³ and subdural hematomas greater than 10mm in thickness or causing more than 5 mm of midline shift should be evacuated, independent of the GCS. An EDH less than 30 cm³, and less than 15mm in maximal thickness, and with less than 5 mm midline shift, in a patient with a GCS of 9 or more without a focal deficit, can be managed non-surgically with close monitoring and repeat CT scans. Frontal or temporal lobe
contusions greater than 20 cm³ associated with midline shift of 5 mm or more, in patients with GCS of 6 to 8 or any parenchymal lesion greater than 50 cm³ should be operated upon. An open (compound) cranial fracture depressed greater than the thickness of cranium should be operated upon to prevent infection. An open (compound) depressed fracture may be treated non surgically if it is not depressed more than 1 cm, there is no dural penetration, no intracranial mass lesion, no frontal sinus involvement, no pneumocephalus, no cosmetic deformity, and no wound contamination or infection.

Decompressive craniectomy (DC) is being increasingly used for patients with severe diffuse TBI and medically refractory intracranial hypertension (Ahmad & Bullock 2011). DC is effective in reducing the ICP and increasing the survival, but has not been shown to improve long term neurological outcome (Li, Timofeev et al. 2010). In fact, there is strong evidence to suggest that DC in patients with severe TBI (GCS 3-8) with medically refractory intracranial hypertension is associated with a worse neurological outcome at 6 months after injury compared to similar patients who were treated with controlled ventilation, mannitol, hypertonic saline, external ventricular drainage, mild hypothermia and barbiturates (Cooper et al. 2011). DC for treatment of medically refractory intracranial hypertension, in severe diffuse TBI, is discouraged till parameters other than ICP control are available, to gauge the success of therapy (Marion 2011). This procedure can still be an effective therapy in very select group of patients such as those undergoing craniotomy for intracranial hematoma (particularly SDH) with significant brain swelling. Unwarranted use of DC may prove counterproductive in terms of neurological recovery in patients with severe TBI.

7. Future directions
7.1 Microdialysis
Microdialysis is an invasive monitoring technique which allows sampling of the extracellular fluid within the brain parenchyma in order to test for a variety of substances. Although a wide variety of substances can be analyzed successfully, glucose, lactate, pyruvate, glycerol, and glutamate are the most commonly employed. Glycerol is monitored primarily as a marker of membrane breakdown, whereas glucose, lactate, pyruvate, and the lactate/pyruvate ratio are used as markers of cerebral energy metabolism. The lactate/pyruvate ratio, in particular, is often employed as an indicator of the brain redox state and an early sign of focal ischemia. Microdialysis probes are usually placed in the frontal white matter in patients with diffuse brain injury, or in the pericontusional tissue in patients with focal radiographic abnormalities (Bellander et al. 2004). Although cerebral microdialysis has been widely used in animal studies for more than 30 years, its use in clinical practice is limited primarily to large academic centers where it is generally used in conjunction with other monitoring devices to provide an early indicator of evolving secondary brain injury. For instance, in cases of cerebral ischemia, the lactate/pyruvate ratio increases markedly, whereas the glucose level declines to near zero. These findings have been shown to correlate with SjV O₂ and PbO₂ measurements, as well as the oxygen extraction fraction as measured by PET (Robertson et al. 1995; Valadka et al. 1998; Hutchinson et al. 2002). When used in conjunction with CPP and ICP monitoring, microdialysis may have a role in early detection of focal (as opposed to global) pathological processes, such as vasospasm or expanding contusions (Valadka & Robertson 2007; Hillered, Vespa, & Hovda 2005).
The data acquired by centers that utilize microdialysis routinely provides considerable insight into the pathophysiology of secondary brain injury in this population. For instance, Vespa et al. have reported persistently low glucose levels in cerebral microdialysate in the first 50 hours following brain injury in patients with poor outcome, which was unrelated to cerebral ischemia (Vespa et al. 2003). This may reflect a disorder of energy metabolism related to ongoing brain injury in patients with severe TBI. Work from the same group has demonstrated that intensive insulin therapy, as practiced in many surgical ICUs, often results in evidence of metabolic stress in patients with TBI (Vespa et al. 2006). Investigators studying the relationship between CPP on cerebral glucose metabolism have noted significant increases in the lactate/pyruvate ratio at CPPs less than 50mmHg which were confined to perilesional tissue. This work would seem to support the contention that susceptibility to ischemic insult is greater in a region of “tissue at risk” adjacent to contused brain (Nordstrom et al. 2003). Data on hyperventilated patients have been conflicting, with some studies reporting no effect (Letarte et al. 1999). In contrast, another study demonstrated that increased glutamate and lactate/pyruvate ratio could be demonstrated in TBI patients hyperventilated within 36 hours of injury, though these changes were seen much less commonly at later time points (Marion et al. 2002). This observation reinforces the hypothesis that sustained hyperventilation is particularly detrimental in the early stages following TBI.

Microdialysis data has also been used to investigate the physiological effects of various therapeutic interventions. Hyperbaric oxygen therapy has been shown to result in a reproducible decrease in lactate and lactate/pyruvate ratio, which was accompanied by improvements in cerebral blood flow, CMRO₂, and ICP (Rockswold et al. 2010). Similarly, microdialysis has been used to investigate the effect of barbiturates and propofol on cerebral energy metabolism. Thiopental coma was shown to reduce lactate in a small number of TBI patients, suggesting reduced anaerobic metabolism (Goodman et al. 1996). In contrast, propofol was not shown to have any significant effect on lactate, pyruvate, or glucose concentrations even when titrated to burst suppression (Johnston et al. 2003). Although both studies involved small numbers of patients, this would seem to suggest that barbiturates are more effective for the prevention of secondary brain injury.

7.2 Biomarkers
One of the major goals of ongoing research in TBI is the identification of reliable biomarkers. The ideal biomarker would enable early diagnosis of underlying brain injury, provide an early indicator of secondary brain injury, and enable clinicians to monitor the patient’s response to therapy. Conceivably, use of a variety of biomarkers specific to different tissue types or mechanisms of injury may help to guide therapy and provide insight into ongoing pathophysiology. Over the past 40 years, a variety of candidate molecules have been evaluated in both clinical settings and in animal models. Perhaps the most widely studied is S100B, a calcium-binding protein that is found in astrocytes. S100B has a half-life of < 60 min in serum; consequently, elevated levels are unlikely to persist for more than 24 hours in the absence of severe TBI (Berger 2006). This protein can be quantified in the serum and in the CSF; the peak serum levels appear to occur roughly 48 hours after the peak CSF concentration is reached (Petzold et al. 2003). Elevated levels of S100B have been shown to correlate with poor outcome, contusion volume, and (inversely) with certain quality of life measures (Raabe et al. 1998; Woertgen, Rothoerl, & Brawanski 2002). Unfortunately, the
time course of S100B release, the dynamics of transport across the blood-brain-barrier, and the patho-physiological implications of elevated S100B levels remain to be determined (Kleindienst et al. 2010). Other candidate biomarkers associated with outcome in TBI patients include neuron specific enolase, a cytoplasm protein found in neuronal tissue, and glial fibrillary acidic protein (GFAP), an intermediate filament protein found in astrocytes (Vos et al. 2004) GFAP, in particular, has been shown to correlate with CT findings and with outcome in trauma patients (Lumpkins et al. 2008; Nylen et al. 2006). Although no large scale studies are available, some investigators suggest that GFAP may prove to be more sensitive than neuron-specific enolase (NSE) or S100B, due to the lack of extracerebral sources (Honda et al. 2010).

Whereas NSE, S100B, and GFAP are markers of cellular breakdown, certain other candidate biomarkers serve as indicators of ongoing pathophysiological processes. For instance, diffuse axonal injury is characterized pathologically by axonal degradation, which is associated with the breakdown of axonal microtubules. This results in the release of microtubule-associated protein tau, which is cleaved into fragments which are known as cleaved-tau (C-tau) (Li, Li et al. 2010). The presence of C-tau in the CSF has been found to be a sensitive indicator of diffuse axonal injury, and levels correlate inversely with clinical improvement (Zemlan et al. 1999). Other putative biomarkers have the potential to allow investigators to differentiate between cell death related to apoptosis as opposed to necrosis. The alpha-II spectrin protein, for example, is a component of the axonal cytoskeleton which is cleaved by enzymes involved in both cellular necrosis (caspase-3) and apoptosis (calpain 1 and 2). Western blot analysis of the alpha-II spectrin breakdown products present in a given sample can therefore provide insight into the predominant mechanism of cellular loss (Li, Li et al. 2010). Preliminary studies using alpha-II spectrin breakdown products in humans have demonstrated that necrosis, mediated by calpain, is the predominant mechanism involved in acute DAI, suggesting that calpain inhibitors may be a potential therapeutic target (Brophy et al. 2009).

7.3 Pharmacotherapy

A major factor contributing to intractable intracranial hypertension following severe TBI is cerebral edema. Both cytotoxic and vasogenic edema contribute to post traumatic cerebral edema (Barzo et al. 1997). Therapeutic interventions directed at mediators of cerebral edema offer potential treatment options for TBI. Aquaporins (AQPs) are integral membrane proteins that form pores in membranes of mammalian cells, and play an important role in development and resolution of cerebral edema (Pasantes-Morales & Cruz-Rangel 2010). AQPs modulation offers a potential therapeutic intervention to prevent or treat brain swelling (Manley et al. 2000; Papadopoulos & Verkman 2008; Taya et al. 2008). Matrix metalloproteinases (MMPs) are zinc dependent endopeptidases involved in the process of tissue remodeling following brain injury from stroke or trauma. MMPs are upregulated following TBI, causing disruption of BBB and cerebral edema in the early phase, followed by neurogenesis and neurovascular remodeling in the later stages of recovery. Thus selective therapeutic blocking of the detrimental effects in the early phase offers the possibility of preventing cerebral edema without disrupting the later reparative phase (Donkin & Vink 2010). A group of neuropeptides released from sensory neurons have been implicated in neurogenic inflammation. Neurogenic inflammation that includes vasodilation, plasma extravasation and neuronal hypersensitivity, has been shown to play a role in the
development of post traumatic cerebral edema. Therapeutic inhibition of neurogenic inflammation offers another potential target to prevent cerebral edema after TBI (Donkin & Vink 2010). Progesterone is another agent with potential therapeutic role in the management of TBI. Progesterone receptors are distributed throughout the central nervous system, and the steroid has neuroprotective properties. Progesterone decreases brain edema, attenuates free radicals and reduces neuronal loss in TBI animal model. There is class II evidence to suggest it may improve neurologic outcome in patients with TBI (Junpeng, Huang, & Qin 2011).

8. Conclusion

TBI is a serious disorder with significant morbidity, mortality and economic implications. It is a dynamic process, and timely intervention can prevent progression of neurological decline. Foundation of acute care is built upon prompt resuscitation and transport from the site of accident to a tertiary care facility, appropriate imaging, and intensive monitoring focused on minimization and prevention of secondary damage. Considerable progress has been made in understanding the physiology of ICP and treatment of intracranial hypertension, but control of ICP does not always translate into good neurological outcome. Better understanding of pathophysiology, identification of newer parameters of brain function, and development of innovative therapeutic modalities is required to improve the outcome from TBI.

9. References


Barzo, P., Marmarou, A., Fatouros, P., Hayasaki, K., & Corwin, F. (1997). Contribution of vasogenic and cellular edema to traumatic brain swelling measured by diffusion-


severe head injury. The Executive Committee of the International Selfotel Trial, J Neurosurg, Vol.92, No. 1, (Jan 2000), pp. 1-6, ISSN 0022-3085


ultrastructural studies, *J Neurosurg*, Vol.82, No. 6, (Jun 1995), pp. 966-971, ISSN 0022-3085


www.intechopen.com


Vialet, R., Albanese, J., Thomachot, L., Antonini, F., Bourgouin, A., Alliez, B., & Martin, C. (2003). Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol, Crit Care Med, Vol.31, No. 6, (Jun 2003), pp. 1683-1687, ISSN 0090-3493


The present two volume book "Brain Injury" is distinctive in its presentation and includes a wealth of updated information on many aspects in the field of brain injury. The Book is devoted to the pathogenesis of brain injury, concepts in cerebral blood flow and metabolism, investigative approaches and monitoring of brain injured, different protective mechanisms and recovery and management approach to these individuals, functional and endocrine aspects of brain injuries, approaches to rehabilitation of brain injured and preventive aspects of traumatic brain injuries. The collective contribution from experts in brain injury research area would be successfully conveyed to the readers and readers will find this book to be a valuable guide to further develop their understanding about brain injury.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: